1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Henogen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease IT-Combination - Acute Graft Versus Host Disease | Phase 1 / Phase 2 | Withdrawn | Henogen | 12 | 2010-01-01 | 2009-04-29 |
| Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664). EBV vaccine (268664) - Epstein Barr Virus (EBV) Infection | Phase 2 | Completed | Henogen | 200 | 2007-02-02 |
Epstein-Barr Virus Infections (1) · Infections (1) · Infectious Mononucleosis (1)
Belgium (1) · Netherlands (1)
Anton V Schattenberg,, MD, PhD, (1)